These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 27178440)
1. Olfactomedin 4 expression and functions in innate immunity, inflammation, and cancer. Liu W; Rodgers GP Cancer Metastasis Rev; 2016 Jun; 35(2):201-12. PubMed ID: 27178440 [TBL] [Abstract][Full Text] [Related]
2. Olfactomedin-4 in digestive diseases: A mini-review. Wang XY; Chen SH; Zhang YN; Xu CF World J Gastroenterol; 2018 May; 24(17):1881-1887. PubMed ID: 29740203 [TBL] [Abstract][Full Text] [Related]
3. Olfactomedin 4 deletion induces colon adenocarcinoma in Apc Liu W; Li H; Hong SH; Piszczek GP; Chen W; Rodgers GP Oncogene; 2016 Oct; 35(40):5237-5247. PubMed ID: 26973250 [TBL] [Abstract][Full Text] [Related]
4. Olfactomedin 4 down-regulates innate immunity against Helicobacter pylori infection. Liu W; Yan M; Liu Y; Wang R; Li C; Deng C; Singh A; Coleman WG; Rodgers GP Proc Natl Acad Sci U S A; 2010 Jun; 107(24):11056-61. PubMed ID: 20534456 [TBL] [Abstract][Full Text] [Related]
5. The regulation of OLFM4 expression in myeloid precursor cells relies on NF-kappaB transcription factor. Chin KL; Aerbajinai W; Zhu J; Drew L; Chen L; Liu W; Rodgers GP Br J Haematol; 2008 Nov; 143(3):421-32. PubMed ID: 18764868 [TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer. Ma H; Tian T; Liang S; Liu X; Shen H; Xia M; Liu X; Zhang W; Wang L; Chen S; Yu L Oncotarget; 2016 Mar; 7(9):10594-605. PubMed ID: 26871282 [TBL] [Abstract][Full Text] [Related]
7. OLFM4 modulates intestinal inflammation by promoting IL-22 Xing Z; Li X; He J; Chen Y; Zhu L; Zhang X; Huang Z; Tang J; Guo Y; He Y Commun Biol; 2024 Jul; 7(1):914. PubMed ID: 39075283 [TBL] [Abstract][Full Text] [Related]
8. Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer. Li H; Kim C; Liu W; Zhu J; Chin K; Rodriguez-Canales J; Rodgers GP Int J Cancer; 2020 Mar; 146(5):1346-1358. PubMed ID: 31241767 [TBL] [Abstract][Full Text] [Related]
9. Regulation of the MIR155 host gene in physiological and pathological processes. Elton TS; Selemon H; Elton SM; Parinandi NL Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696 [TBL] [Abstract][Full Text] [Related]
10. Olfactomedin 4, a novel marker for the differentiation and progression of gastrointestinal cancers. Yu L; Wang L; Chen S Neoplasma; 2011; 58(1):9-13. PubMed ID: 21067260 [TBL] [Abstract][Full Text] [Related]
11. Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma. Duan C; Liu X; Liang S; Yang Z; Xia M; Wang L; Chen S; Yu L J Cell Mol Med; 2014 May; 18(5):863-74. PubMed ID: 24495253 [TBL] [Abstract][Full Text] [Related]
12. Olfactomedin 4 deficiency promotes prostate neoplastic progression and is associated with upregulation of the hedgehog-signaling pathway. Li H; Liu W; Chen W; Zhu J; Deng CX; Rodgers GP Sci Rep; 2015 Nov; 5():16974. PubMed ID: 26581960 [TBL] [Abstract][Full Text] [Related]
13. Olfactomedin-4 improves cutaneous wound healing by promoting skin cell proliferation and migration through POU5F1/OCT4 and ESR1 signalling cascades. Klaas M; Mäemets-Allas K; Heinmäe E; Lagus H; Arak T; Eller M; Kingo K; Kankuri E; Jaks V Cell Mol Life Sci; 2022 Feb; 79(3):157. PubMed ID: 35218417 [TBL] [Abstract][Full Text] [Related]
14. Deletion of the olfactomedin 4 gene is associated with progression of human prostate cancer. Li H; Rodriguez-Canales J; Liu W; Zhu J; Hanson JC; Pack S; Zhuang Z; Emmert-Buck MR; Rodgers GP Am J Pathol; 2013 Oct; 183(4):1329-38. PubMed ID: 24070418 [TBL] [Abstract][Full Text] [Related]
15. Olfactomedin 4 mediation of prostate stem/progenitor-like cell proliferation and differentiation via MYC. Li H; Chaitankar V; Zhu J; Chin K; Liu W; Pirooznia M; Rodgers GP Sci Rep; 2020 Dec; 10(1):21924. PubMed ID: 33318499 [TBL] [Abstract][Full Text] [Related]
16. Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis. Grover PK; Hardingham JE; Cummins AG Cancer Metastasis Rev; 2010 Dec; 29(4):761-75. PubMed ID: 20878207 [TBL] [Abstract][Full Text] [Related]
17. Olfactomedin-4 is a candidate biomarker of solid gastric, colorectal, pancreatic, head and neck, and prostate cancers. Guette C; Valo I; Vétillard A; Coqueret O Proteomics Clin Appl; 2015 Feb; 9(1-2):58-63. PubMed ID: 25400027 [TBL] [Abstract][Full Text] [Related]
18. Olfactomedin 4 associates with expression of differentiation markers but not with properties of cancer stemness, EMT nor metastatic spread in colorectal cancer. Jaitner S; Pretzsch E; Neumann J; Schäffauer A; Schiemann M; Angele M; Kumbrink J; Schwitalla S; Greten FR; Brandl L; Klauschen F; Horst D; Kirchner T; Jung A J Pathol Clin Res; 2023 Jan; 9(1):73-85. PubMed ID: 36349502 [TBL] [Abstract][Full Text] [Related]
19. Olfactomedin 4 inhibits cathepsin C-mediated protease activities, thereby modulating neutrophil killing of Staphylococcus aureus and Escherichia coli in mice. Liu W; Yan M; Liu Y; McLeish KR; Coleman WG; Rodgers GP J Immunol; 2012 Sep; 189(5):2460-7. PubMed ID: 22844115 [TBL] [Abstract][Full Text] [Related]
20. Weiwei Decoction alleviates gastric intestinal metaplasia through the olfactomedin 4/nucleotide-binding oligomerization domain 1/caudal-type homeobox gene 2 signaling pathway. Zhou DS; Zhang WJ; Song SY; Hong XX; Yang WQ; Li JJ; Xu JQ; Kang JY; Cai TT; Xu YF; Guo SJ; Pan HF; Li HW World J Gastrointest Oncol; 2024 Jul; 16(7):3211-3229. PubMed ID: 39072182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]